Portfolio company EyeBio acquired by Merck & Co. ($1.3B upfront, up to $1.7B in milestones).
EyeBio is a subsidiary of Merck focused on developing therapies aimed at protecting, restoring, and improving vision for people living with eye diseases, particularly retinal diseases
EyeBio is a subsidiary of Merck focused on developing therapies aimed at protecting, restoring, and improving vision for people living with eye diseases, particularly retinal diseases.